| rs8045120 |
chr16 |
84741149 |
0.00013 |
G |
T |
Type 2 diabetes |
USP10 |
intron |
17463246
|
| rs3764286 |
chr16 |
84741343 |
0.000879 |
C |
T |
Parkinson's disease |
USP10 |
intron |
17052657
|
| rs1862794 |
chr16 |
84750595 |
0.000834 |
C |
T |
Type 2 diabetes |
USP10 |
intron |
17463246
|
| rs1862794 |
chr16 |
84750595 |
0.000287 |
C |
T |
Multiple complex diseases |
USP10 |
intron |
17554300
|
| rs41422347 |
chr16 |
84750816 |
0.000119 |
T |
C |
Multiple complex diseases |
USP10 |
intron |
17554300
|
| rs12149617 |
chr16 |
84754898 |
0.000148 |
G |
A |
Multiple complex diseases |
USP10 |
intron |
17554300
|
| rs12149617 |
chr16 |
84754898 |
0.000391 |
G |
A |
Coronary Artery Disease |
USP10 |
intron |
17634449
|
| rs41386649 |
chr16 |
84769024 |
0.000264 |
C |
T |
Multiple complex diseases |
USP10 |
intron |
17554300
|
| rs17763304 |
chr16 |
84771176 |
0.000713 |
C |
T |
Type 2 diabetes |
USP10 |
intron |
17463246
|
| rs17763304 |
chr16 |
84771176 |
0.000342 |
C |
T |
Multiple complex diseases |
USP10 |
intron |
17554300
|
| rs17763304 |
chr16 |
84771176 |
0.000782 |
C |
T |
Coronary Artery Disease |
USP10 |
intron |
17634449
|
| rs4510001 |
chr16 |
84774120 |
0.000571 |
T |
C |
Type 2 diabetes |
USP10 |
intron |
17463246
|
| rs4510001 |
chr16 |
84774120 |
0.00017 |
T |
C |
Multiple complex diseases |
USP10 |
intron |
17554300
|
| rs744839 |
chr16 |
84774436 |
0.000972 |
C |
T |
Type 2 diabetes |
USP10 |
intron |
17463246
|
| rs11149680 |
chr16 |
84780907 |
0.0003 |
C |
T |
Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes |
USP10 |
intron |
22628534
|
| rs8051512 |
chr16 |
84781101 |
0.000231 |
C |
G |
Parkinson's disease |
USP10 |
intron |
17052657
|
| rs16974538 |
chr16 |
84783658 |
0.000031 |
T |
G |
Cognitive performance |
USP10 |
intron |
19734545
|
| rs17831494 |
chr16 |
84785378 |
0.000806 |
G |
A |
Type 2 diabetes |
USP10 |
intron |
17463246
|
| rs17831494 |
chr16 |
84785378 |
0.0000903 |
G |
A |
Multiple complex diseases |
USP10 |
intron |
17554300
|
| rs4783057 |
chr16 |
84785672 |
0.000374 |
G |
A |
Response to taxane treatment (placlitaxel) |
USP10 |
intron |
23006423
|
| rs4783057 |
chr16 |
84785672 |
0.00043 |
G |
A |
Response to cytidine analogues (gemcitabine) |
USP10 |
intron |
24483146
|
| rs6564074 |
chr16 |
84786250 |
0.000193 |
C |
A |
Response to taxane treatment (placlitaxel) |
USP10 |
intron |
23006423
|
| rs6564074 |
chr16 |
84786250 |
0.000148 |
C |
A |
Response to cytidine analogues (gemcitabine) |
USP10 |
intron |
24483146
|
| rs7186789 |
chr16 |
84786855 |
0.000613 |
T |
G |
Depression (quantitative trait) |
USP10 |
intron |
20800221
|
| rs7205632 |
chr16 |
84796402 |
0.000585 |
A |
T |
Type 2 diabetes |
USP10 |
intron |
17463246
|
| rs7205632 |
chr16 |
84796402 |
0.000414 |
A |
T |
Multiple complex diseases |
USP10 |
intron |
17554300
|
| rs7205632 |
chr16 |
84796402 |
0.000488 |
A |
T |
Response to cytidine analogues (gemcitabine) |
USP10 |
intron |
24483146
|
| rs12932018 |
chr16 |
84796603 |
0.000006 |
A |
G |
Response to mTOR inhibitor (everolimus) |
USP10 |
cds-synon |
24009623
|
| rs2641688 |
chr16 |
84801751 |
0.000653 |
G |
A |
Response to cytidine analogues (gemcitabine) |
USP10 |
intron |
24483146
|